Stem cell doses necessary for engraftment after myeloablative therapy as defined for fresh transplants vary largely. Loss of CD34
In the last decade peripheral blood stem cells have become the preferred transplant source for haematological recovery after high-dose chemotherapy in malignant diseases. [1] [2] [3] [4] [5] [6] Presently, two methods of peripheral stem cell collection are in use, ie conventional leucapheresis 7 and withdrawal of 450-1000 ml of whole blood. 1, 2, [8] [9] [10] With both methods, stem cells are mobilised into the blood by means of growth factors with or without chemotherapy. After leucapheresis, cells are processed, cryo-preserved and stored in liquid or gas-phase nitrogen until reinfusion. In the whole blood method, originally described by our group, 8, 11 the collected blood is stored unprocessed in bags for 24 to 72 h at 4°C. 1, [10] [11] [12] [13] Some groups use a combination of both methods by preserving the leucapheresis product at 4°C. [14] [15] [16] An important difference between both types of transplants is that the whole blood transplants, although effective in terms of recovery, contain five to 10-fold less CD34
+ cells than leucapheresis products. Apart from this discrepancy the loss of CD34
+ cells necessary for haematological recovery after transplantation using leucapheresis material is a matter of dispute in literature. Ranges from 0.75 to 8.0 ϫ 10 6 CD34 + cells/kg body weight are reported to be sufficient for haematological recovery. 4, 6, [17] [18] [19] [20] We hypothesised that both types of discrepancies might not only depend on pre-treatment and underlying disease 6, 21 of the patients studied, but also on the quantity of viable cells after harvesting and storage. In a previous study we demonstrated that purified CD34 + cells, upon freeze-thawing, show a varying amount of early apoptosis apart from cell death. 22 This early apoptosis could be detected with a new method including the vital stain Syto16, which was shown to probe functionally inactive CD34
+ cells, undetectable with conventional viability probes. 22 In the present study we therefore determined the quantity of viable CD34-positive cells in both types of stem cell sources of lymphoma patients 11, 21 and redefined the threshold numbers of CD34 + cells necessary for haematological recovery. 11 with whole blood reinfusion. G-CSF (300 g) was given from day +1 until recovery of ANC Ͼ0.5 ϫ 10 9 /l. In Table 1 haematological recovery data of both lymphoma groups are summarised.
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Materials and methods
Patients and chemotherapy
Harvesting and preservation of leucapheresis stem cell grafts
Leucapheresis was performed on a Fenwall CS 3000 (Baxter Healthcare, Deerfield, IL, USA). Ten litres of blood were processed during each apheresis. The leucapheresis material was subsequently frozen in autologous plasma (MNC Ͻ200 ϫ 10 6 /ml) in 10% dimethyl sulfoxide (DMSO, Acros Organics, Fairlawn, NJ, USA) using controlled freezing with a Kryo10 (Planer Biomed, Sunbury, UK). For reinfusion, leucapheresis bags were rapidly thawed near the bedside at 37°C.
For whole blood collection, 2 volumes of 500 ml blood from the antecubital vein were collected in PVC bags containing 70 ml CPDA-1 as anticoagulant (NPBI, EmmerCompascuum, The Netherlands). Both volumes were col- /l, respectively). LP = leucapheresis product preserved in liquid nitrogen, analyses performed immediately after thawing; WB = whole blood transplants kept at 4°C for 3 days without further processing and thereafter reinfused; NR = no recovery until death.
lected with an interval of at least 30 min to prevent hypotension while 500 ml of saline 0.9% was administered during phlebotomy. After collection, the bags were sealed and stored unprocessed at 4°C in a controlled refrigerator until re-infusion 72 h later.
Analysis of stem cell grafts
For analysis of leucapheresis grafts, vials of cryo-preserved leucapheresis material were rapidly thawed by dilution (1:10) in PBS/0.1% BSA kept at 37°C and containing 200 g DNAse/ml (Boehringer Mannheim, Mannheim, Germany) to prevent clotting. Since in most cases more than one leucapheresis session had been applied, the contents of vials, cryo-preserved after the different leucapheresis sessions, were mixed in such a way as to represent the content of the actual transplant.
CD34
+ analysis
Samples were incubated with anti-CD34 APC (Becton Dickinson, San Jose, CA, USA), anti-CD45 FITC (Immunotech, Marseille, France) or control anti-IgG1 and 7-AAD for 15 min at room temperature (modified ISHAGE 23 ). If necessary red cells were lysed by using orthomune lysing reagent (Ortho Diagnostic Systems, Raritan, NJ, USA).
Apoptosis and viability analysis
Viability was measured using either trypan blue or 7-AAD (7-amino actinomycin D, Via-Probe, PharMingen, San Diego, CA, USA).
For apoptosis analysis cells (5 ϫ 10 6 /ml at most) were incubated with anti-CD34 APC alone, washed and subsequently incubated with 1-5 nm Syto16 (Molecular Probes, Eugene, OR, USA) and 7-AAD in DMEM (Flow Labs, Irvine, UK) without phenol red for 45 min in the presence of PSC833 (a gift from Novartis, Basel, Switzerland). 22 Cells were subsequently washed in 0.1% PBS/BSA and analysed on a FACSCalibur with Cell Quest software (Becton Dickinson) for CD34
+ cell content and apoptosis analysis. Syto16 was measured in FL1, 7-AAD in FL3 and CD34 in FL4. Syto16 emits both in FL2 and FL3. To avoid compensation problems low concentrations (Ͻ5 nm, usually 1 nm) have been used. The small spectral overlap in FL3, which is seen at Syto16 concentration Ͻ5 nm could be adequately compensated using FL2. In addition, under these conditions it was even possible to use FL2 for additional PE labelling. A representative example of the colour relationship between Syto16 and 7-AAD has been published before. 22 We have shown that the Syto16 assay is able to probe apoptosis in CD34
+ cells earlier than the well-known compound annexin V, 22 (de Boer, manuscript submitted). Therefore, data shown were determined by Syto16 staining. Necrosis following apoptosis was defined as secondary necrosis.
Assessment of threshold numbers of CD34
+ cells for haematological recovery
For assessment of threshold values for adequate haematological recovery, a series of cut-off points in the doses of reinfused CD34
+ cells/kg body weight were chosen. Each cut-off point defined two groups of patients: one with a number of CD34
+ cells above and one below that particular cut-off point. The cut-off point that showed the greatest difference in median number of days until recovery between these groups was determined. Subsequently, the CD34 + dose corresponding to the beginning of a plateau in difference was chosen to define the threshold value for adequate haematological recovery (see example Figure 1 ). In addition, the differences between the groups thus defined were analysed for significance using the Mann-Whitney U test. + cells for haematological recovery. Shown is the difference in median recovery between the two groups (y axis) separated by cut-off values (closed circles) of CD34 + cell dose as described in Materials and methods. The arrow indicates the threshold value. The lowest dose of CD34 still shows a relatively small difference in haematological recovery between both groups of patients (in this case 2.8 ϫ 10 6 /kg). The alternative, ie the first CD34 + dose that resulted in a large difference (2.3 ϫ 10 6 /kg in this case) was not chosen to circumvent any danger of underestimating the dose of CD34 + necessary for recovery.
Statistical analysis
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shown are Spearman-rank (r s ). Differences were calculated by means of the Mann-Whitney U test. A P value lower than 0.05 was considered to indicate a statistically significant difference.
Results
Apoptosis analysis in stem cell grafts
Following our previous study in purified cells 22 we used the vital stain Syto16 combined with 7-AAD and CD34 labelling, to determine apoptosis and necrosis following cryopreservation in leucapheresis material of lymphoma patients (n = 49). Non-apoptotic cells were defined as Syto16 high /7-AAD − cells, whereas apoptotic and secondary necrotic cells were defined as Syto16 low /7-AAD − and Syto16 low /7-AAD + cells, respectively. Figure 2 shows the results for the 49 leucapheresis transplants at day of transplant. In the frozen-thawed leucapheresis material the mean percentages of viable cells were 72% using 7-AAD alone, but only 42% using Syto16 staining. To check if loss of quality was different between poor and good mobilisers (mean of 1.5 leucapheresis procedures, range 1-4), the whole group of patients for which the quality loss has been shown in Figure 2 was divided into four groups defined by differences in total numbers of mobilised CD34 + cells. There was no trend for an altered recovery of viability depending on the initial CD34 dose. In addition, when using continuous function no correlations were found between the initial number of CD34 + cells/kg and both the . Frozen-thawed leucapheresis material was analysed directly after thawing and compared with the freshly obtained non-frozen graft. A significant loss of viable CD34
+ cells was detected compared to the unfrozen graft (first bar). Syto16 detects about twice as much non-viable cells as compared to trypan blue or 7-AAD (42%, range 6-94% and 72%, range 25-99, respectively). *The freshly obtained leucapheresis material was retrospectively analysed. For the viability in that material the trypan blue exclusion test was used and not the 7-AAD or Syto16 test on gated CD34 + cells. Since in parallel experiments the trypan blue exclusion test for the whole blood cell population and the 7-AAD test on gated CD34
+ cells are in excellent agreement (de Boer, manuscript submitted), we considered viability measured by trypan blue in the fresh material similar to 7-AAD. Similarly, in fresh material a minor decrease of viability was observed when using Syto16 or 7-AAD defined viability on gated CD34 + cells. Differences between 'fresh' values on the one hand and each of the cryopreservation ('cryo') values were highly significant (P Ͻ 10 −10) ; differences between 'Syto cryo' and '7-AAD cryo' were highly significant (P Ͻ 10 −20 ).
7-AAD (r s = Ϫ0.064, P = 0.66) and the Syto16/7-AAD (r s = Ϫ0.004, P = 0.97) recovery, showing independence of viability recovery from success of mobilization.
Threshold numbers of viable CD34 + cells after correction for apoptosis
In Figure 3 haematological recovery as a function of stem cell dose is depicted for the group of lymphoma patients transplanted with leucapheresis material. The figure clearly shows that recovery times improve with increasing doses of CD34 + cells, although there is no continuous regression between the variables.
Using the method for determining threshold values for adequate recovery as described in Materials and methods, for leucapheresis material 3.0 ϫ 10 6 CD34 + /kg body weight was required for adequate ANC recovery and 2.8 ϫ 10 Relation between haematological recovery in lymphoma patients and CD34 dose in leucapheresis grafts after apoptosis correction. The figure shows haematological recovery of lymphoma patients (n = 49) after high-dose chemotherapy (BEAM) and rescue with frozen-thawed leucapheresis material plotted against CD34 + cell dose. The number of re-infused CD34 + cells is shown either corrected using trypan blue (upper panels, a, b) in the fresh material and in the frozen-thawed leucapheresis material, the actual transplant, corrected using 7-AAD (middle panels, c, d) and Syto16 (lower panels, e, f). Thresholds for hematological recovery are depicted as solid vertical lines and were established as outlined in Materials and methods and Figure 1 . The left panels (a, c, e) represent platelet (Ͼ50 ϫ 10 9 /l), the right panels (b, d, f) the ANC recovery (Ͼ0.5 ϫ 10 9 /l). The data for platelets Ͼ20 ϫ 10 9 /l are not shown for reasons of clarity and similarity to the data shown for platelets Ͼ50 ϫ 10 9 /l, but are summarised in Table 2. referring to the numbers of CD34 + cells in fresh transplant material (Table 2) .
When taking into account the variable loss of viable cells upon freeze-thawing Figure 3a and b have been adapted to show the relationship between recovery and transplanted numbers of viable non-apoptotic CD34 + cells using both the 7-AAD and the Syto16 assay: both the platelet recovery curve (Figure 3c, e) and the nucleated cell recovery (Figure  3d, f) show a clear shift towards lower numbers of CD34 + cells/kg body weight when using 7-AAD in the frozenthawed graft (compare Figure 3c, d with 3a and b, respectively) and a further shift when using Syto16 fluorescence (Figure 3e and f) .
Correlations of both fresh CD34 + doses or 7-AAD defined doses or Syto16/7-AAD defined doses all showed significance for ANC recovery (r = −0.37 to Ϫ0.46, P Ͻ 0.008), platelet (Ͼ20) recovery (r = −0.46 to Ϫ0.64, P Ͻ 0.001) and platelet (Ͼ50) recovery (r = −0.41 to Ϫ0.57, P Ͻ 0.005). Based on these adapted CD34 + doses, new threshold values for haematological recovery have been calculated compared to the fresh values: these values decreased by a factor of 1.3 (7-AAD alone) and 2.4 (Syto16/7-AAD) and are shown in Table 2 and Figure 3 . Figure 3 shows that, based on the viability recoveries of the whole group of 49 patients, thresholds segregate the badly recovering patients from the other patients fairly well.
Apoptosis analysis in whole blood transplants
Whole blood transplants contain relatively low numbers of CD34 + cells 11 but reasonable recovery is still reached. Therefore we investigated the same parameters described above for leucapheresis material for whole blood transplants of lymphoma patients. When using 7-AAD positivity or Syto16 uptake, the (day 3) number of viable non-apoptotic cells was very similar to the number determined immediately after (day 0) venesection ( Figure 4) . With regard to the patient group that received whole blood transplants threshold values were 0.4 ϫ 10 6 (ANC), 0.3 ϫ 10 6 (platelets Ͼ20) and 0.4 ϫ 10 6 (platelets Ͼ50) CD34 + cells/kg body weight ( Figure 5 and Table 2 ). The minor 
Figure 4 Viability of CD34
+ cells in whole blood grafts determined with different viability/apoptosis assays. Whole blood grafts (n = 45) were assayed for viability by 7-AAD and Syto16 on both day 0 (d0, immediately after withdrawal) and day 3 (d3, just before reinfusion). Only a slight, although significant (P = 0.0003), decrease of viability was seen at day 3 and only when using the Syto16 method.
Bone Marrow Transplantation changes in viability ( Figure 4) were reflected in minor changes of threshold values when viability analysis was applied (factor 1.1 at most) and therefore only small shifts of the recovery curves were seen ( Figure 5 ). As for the leucapheresis group our approach for establishment of threshold value segregates badly recovering patients from others.
Correlations with recovery were: for ANC r s = Ϫ0.57, both 7-AAD and Syto16/7-AAD (P Ͻ 0.0001). The values for platelets Ͼ20 were r s = Ϫ0.60 (P Ͻ 0.0001) and for platelets Ͼ50, r s = Ϫ0.52 (P Ͻ 0.0001) for both 7-AAD and Syto16/7-AAD.
Discussion
In our institution patients with poor risk non-Hodgkin's lymphoma, resistant to or relapsing after frontline therapy, receive high-dose myelo-ablative chemotherapy with subsequent haematological rescue by transplantation of (conventionally) frozen-thawed leucapheresis material or G-CSF mobilised unprocessed whole blood. The group of patients that received whole blood underwent an adapted myelo-ablative scheme in which the etoposide is omitted from the conventional BEAM 21 scheme but with a concomitant increase in ara-C dose. 11 This adaptation helps to deliver the chemotherapy in 72 h, thereby preventing the storage time of whole blood exceeding 3 days. 11, 14, 24 A remarkable feature of whole blood transplantation is that only small numbers of CD34 + cells are sufficient to result in acceptable haematological recovery.
Various studies report threshold numbers of CD34 + cells necessary for haematological recovery, but these values differ largely. 4, 5, [17] [18] [19] [20] 25 One possible explanation for this variation could be that leucapheresis and cryopreservation induces variable loss of viable, functionally active CD34 + cells and that the quality of performance of these processes differs largely between different institutes. An additional important consideration is that normally no re-evaluation of the graft takes place after thawing 26, 27 and the number of reinfused CD34
+ cells is determined only once by sampling the freshly collected transplant and performing a stan- dard viability assay like trypan blue exclusion. However, even when one re-evaluates viability after freeze-thawing using the trypan blue exclusion test, viability is typically 80% or higher. The same percentages were found in our study when using 7-AAD both in the whole population (not shown) and in gated CD34 + cells. Importantly, these dyes detect only permeable, necrotic cells. 28, 29 Using a new assay, 22 which detects early apoptosis, we established that 58% of the CD34 + cells found in thawed leucapheresis products was apoptotic and/or secondary necrotic. This percentage by far exceeded the percentages determined with 7-AAD. In addition, this approach resulted in a large increase in the range of viability found in the stem cell transplants. This technique therefore enables unmasking of patients with bad haematological recovery who presumably received high doses of CD34 + cells as measured by conventional assays. In our study due to the limited total number of patients with bad recovery, only a few such cases are evident.
So, the freeze-thawing process indeed seems to induce extensive early apoptosis in stem cell transplants. On the other hand, the quality of the whole blood transplants remained remarkably good during 3 days of preservation at 4°C, with only small increases of apoptosis and cell death. The same observation was made for leucapheresis material stored at 4°C (96% viability using the Syto16 assay, not shown). This is in agreement with other studies that show safe preservation of leucapheresis material at 4°C for 24 h, 16, 30 72 10 or even 120 h, 31 although no early apoptosis was measured in these studies.
When reconsidering the threshold values for haematological recovery in the lymphoma patient group that received leucapheresis material, the mean number of Syto16 defined reinfused CD34
+ cells appeared to be a factor 2.3 lower than based on conventional viability analysis in the unfrozen leucapheresis material. The very large (7-to 9-fold, Table 2 ) difference in threshold levels between both types of transplant when using fresh material was reduced to a factor of 3.4 using the Syto16 assay. Although the whole blood and leucapheresis groups are not strictly identical in terms of conditioning, the further similarity in patient characteristics and pre-treatment suggest that those groups can be compared. We therefore conclude that there must be an additional factor that explains the 'residual'gap of a factor of 3.4.
When including additional markers on CD34 + cells better correlations with haematological recovery have been found compared to CD34 alone. 18, 32 Therefore our next step will be to determine the transplanted numbers of CD34 + subpopulations among others in transplants in order to explain the residual difference in threshold values for haematological recovery.
In conclusion, cryo-preservation of grafts induces a loss of quantity of viable CD34 + cells, which is due to early but irreversible apoptosis. This loss is highly variable and far more extensive than evident from conventional viability assays. The assessment of this type of injury offers, at least in part, an explanation for the varying numbers of CD34 + cells found necessary for haematological recovery after stem cell transplantation and may further help to explain why whole blood transplantation is possible with relatively low doses of CD34 + cells. In addition, a systematic control for viability of CD34 + cells, in terms of not only cell dead but also early apoptosis, after freeze-thawing, ie immediately before reinfusion, is highly recommended.
